{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-002741","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2022-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.706019+00:00","generated_at":"2026-06-27T01:52:38.030599+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"GlycoMimetics reports cash $90.3M; Phase 3 uproleselan data still after 2022","bullets":["Cash and equivalents $90.3M at Dec 31, 2021 vs $137.0M at Dec 31, 2020; revenue fell to $1.2M from $10.2M.","Pivotal Phase 3 uproleselan trial in relapsed/refractory AML completed enrollment (388 patients); top-line data expected after year-end 2022.","NCI Phase 2/3 registration trial (newly diagnosed AML) completed Phase 2 enrollment (267 patients); interim analysis planned.","Apollomics initiated Phase 3 uproleselan trial in Greater China in November 2021 after Breakthrough Therapy designation.","Expanded executive team: hired Lisa DeLuca (VP Regulatory), Bruce Johnson (SVP/Chief Commercial Officer), Deepak Tiwari (VP Technical Operations)."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-002741","json":"https://secwatch.observer/filing/0001558370-22-002741.json","markdown":"https://secwatch.observer/filing/0001558370-22-002741.md","text":"https://secwatch.observer/filing/0001558370-22-002741.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000155837022002741/0001558370-22-002741-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000155837022002741/glyc-20220303x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T01:52:38.030599+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}